Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 453.

https://doi.org/10.1182/blood-2023-187371

Published: 2023

Journal Articles

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Vladan Vucinic, Janine Kirchberg, Mandy Brueckner, Patrick Born, Luise Fischer, Enrica Bach, Nora Grieb, Simone Heyn, Christina Kloetzer, Klaus H Metzeler, Sandra Hoffmann, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Sebastian Schwind, Song-Yau Wang, Madlen Jentzsch, Uwe Platzbecker, Maximilian Merz

Blood (2023) 142 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2023-182222

Published: 2023

Journal Articles

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2023-188367

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 820.

https://doi.org/10.1182/blood-2023-187419

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Impact of Typical and Atypical Complex Karyotype Subgroups on Outcome of AML Patients Undergoing Allogeneic Stem Cell Transplantation

Jule Ussmann, Anne Weigert, Lara Bischof, Dominic Brauer, Donata Backhaus, Claudia Diener, Maximilian Merz, Vladan Vucinic, Klaus H Metzeler, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2023) 142 (Supplement 1): 2244.

https://doi.org/10.1182/blood-2023-179713

Published: 2023

Journal Articles

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2023-174059

Published: 2023

Journal Articles

A Novel and Cost-Efficient Measurable Residual Disease (MRD) Detection Assay Using a Single Molecule Molecular Inversion Probe-Based Next Generation Sequencing (NGS) Assay Predicts Overall Survival in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Simon M. Krauß, Tara Holloway, Lara Bischof, Donata Backhaus, Dominic Brauer, Jule Ussmann, Anne Weigert, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch, Klaus H Metzeler

Blood (2023) 142 (Supplement 1): 3616.

https://doi.org/10.1182/blood-2023-181728

Published: 2023

Journal Articles

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias

Blood (2023) 141 (8): 955–960.

https://doi.org/10.1182/blood.2022016411

Published: 2023

Includes: Supplemental data

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Madlen Jentzsch, Lara Bischof, Jule Ussmann, Donata Backhaus, Dominic Brauer, Klaus H. Metzeler, Marco Herling, Maximilian Merz, Vladan Vucinic, Georg-Nikolaus Franke, Uwe Platzbecker, Sebastian Schwind

Blood (2022) 140 (Supplement 1): 10601–10602.

https://doi.org/10.1182/blood-2022-164842

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature

Sayantanee Dutta, Paul Kerbs, Maja Rothenberg-Thurley, Bianka Ksienzyk, Stefan Krebs, Helmut Blum, Karsten Spiekermann, Klaus H. Metzeler, Tobias Herold, Sebastian Vosberg, Philipp A. Greif

Blood (2022) 140 (Supplement 1): 8912–8913.

https://doi.org/10.1182/blood-2022-168939

Published: 2022

Journal Articles

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Marie Schneider, Clara Rolfs, Matthias Trumpp, Susann Winter, Luise Fischer, Mandy Richter, Victoria Menger, Kolja Nenoff, Nora Grieb, Anne Sophie Kubasch, Klaus H. Metzeler, Katja Sockel, Christian Thiede, Lorenz C Hofbauer, Andreas Roth, Andreas Bruederle, Janghee Woo, Michael Cross, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4011–4012.

https://doi.org/10.1182/blood-2022-163246

Published: 2022

Journal Articles

Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Lara Bischof, Elizabeth Gaston, Jule Ussmann, Juliane Grimm, Marius Bill, Dominic Brauer, Donata Backhaus, Lisa Herrmann, Maximilian Merz, Marco Herling, Klaus H. Metzeler, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2022) 140 (Supplement 1): 7750–7751.

https://doi.org/10.1182/blood-2022-169478

Published: 2022

Journal Articles

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Alessia Fraccaroli, Elena Stauffer, Katrin Koch, Klaus Hirschbühl, Stephan Breitkopf, Frank Ziemann, Heidrun Drolle, Maja Rothenberg-Thurley, Annika Maria Dufour, Klaus H. Metzeler, Michael von Bergwelt, Karsten Spiekermann, Andreas Hausmann, Christoph Schmid, Mareike Verbeek, Tobias Herold, Johanna Tischer

Blood (2022) 140 (Supplement 1): 4882–4883.

https://doi.org/10.1182/blood-2022-167299

Published: 2022

NARROW

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Impact of Typical and Atypical Complex Karyotype Subgroups on Outcome of AML Patients Undergoing Allogeneic Stem Cell Transplantation

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

A Novel and Cost-Efficient Measurable Residual Disease (MRD) Detection Assay Using a Single Molecule Molecular Inversion Probe-Based Next Generation Sequencing (NGS) Assay Predicts Overall Survival in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only